New Clinical Trial May Lead to Less Chemo in HER-2+ Breast Cancer Patients
FEBRUARY 3 — Breast cancer accounts for 14% of all diagnosed cancer cases in the US and remains one of the most common causes of death among women in the country.
HER-2+ breast cancer is a type of cancer with a high presence of human epidemic growth factor receptor 2 (HER2), a protein that promotes the growth of cancer cells...
Become a Subscriber!
You have read all of your free articles this month. Select a plan below to start your subscription today.
Already a subscriber? Login
